Skip to main content
Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria
Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.
Mid-stage Data on Allena's Hyperoxaluria Drug Fuel Optimism Ahead of Pivotal Readout
Ahead of the pivotal data of its lead experimental drug for hyperoxaluria, Allena Pharmaceuticals revealed interim data from a small mid-stage study on Wednesday, that signaled the drug confers benefits in certain patients with advanced chronic kidney disease (CKD) that are at risk of systemic oxalosis, a potentially life-threatening condition.
Subscribe to Life Style